NKCx Histopathological outcome* within 12 months after cervix cytology in 2021
571 Dalarna

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 227 2.9% 419 5.4% 18 0.2% 1 0.0% . . . . 7144 91.5% 7809 100.0%
ASCUS 56 8.4% 305 45.9% 42 6.3% 2 0.3% . . 3 0.5% 257 38.6% 665 100.0%
LSIL 37 4.5% 475 57.8% 142 17.3% 1 0.1% 3 0.4% 1 0.1% 163 19.8% 822 100.0%
Atypical glandular cells/AGC 16 30.8% 14 26.9% . . 4 7.7% 1 1.9% 1 1.9% 16 30.8% 52 100.0%
Unclear atypia 3 30.0% 4 40.0% 1 10.0% . . . . . . 2 20.0% 10 100.0%
ASC-H 7 4.6% 64 41.8% 74 48.4% 2 1.3% 3 2.0% . . 3 2.0% 153 100.0%
HSIL 1 0.4% 34 15.2% 174 77.7% 3 1.3% 6 2.7% . . 6 2.7% 224 100.0%
Suspected Adenocarcinom . . . . . . 1 14.3% 1 14.3% . . 5 71.4% 7 100.0%
Malignant tumor with unclear origin . . . . . . . . . . . . 1 100.0% 1 100.0%
Squamous cell cancer . . . . 1 100.0% . . . . . . . . 1 100.0%
Totalt 347 3.6% 1315 13.5% 452 4.6% 14 0.1% 14 0.1% 5 0.1% 7597 78.0% 9744 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category
Cancer:
M80009, M80703, M81403